BridgeBio Oncology Therapeutics (BBOT) Financials

BridgeBio Oncology Therapeutics logo
$1.94 -0.04 (-2.02%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.93 -0.01 (-0.46%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for BridgeBio Oncology Therapeutics

Annual Income Statements for BridgeBio Oncology Therapeutics

This table shows BridgeBio Oncology Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-0.04 -74 -134
Consolidated Net Income / (Loss)
-0.04 -74 -134
Net Income / (Loss) Continuing Operations
-0.04 -74 -134
Total Pre-Tax Income
-0.04 -74 -134
Total Operating Income
-0.04 -81 -146
Total Gross Profit
0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00
Operating Revenue
- 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
0.04 81 146
Selling, General & Admin Expense
0.04 7.76 25
Research & Development Expense
- 73 121
Total Other Income / (Expense), net
0.00 6.59 12
Interest & Investment Income
0.00 6.38 11
Other Income / (Expense), net
0.00 0.21 0.43
Basic Earnings per Share
$0.00 ($5,756.41) ($4.30)
Weighted Average Basic Shares Outstanding
0.00 12.90K 31.14M
Diluted Earnings per Share
$0.00 ($5,756.41) ($4.30)
Weighted Average Diluted Shares Outstanding
0.00 12.90K 31.14M
Weighted Average Basic & Diluted Shares Outstanding
- 23.51M 80.03M

Quarterly Income Statements for BridgeBio Oncology Therapeutics

This table shows BridgeBio Oncology Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 49 - - - 37
Net Income / (Loss) Attributable to Common Shareholders
1.14 4.65 -17 2.07 -22 -28 -33 -92 -42 -56 -21
Consolidated Net Income / (Loss)
1.14 4.65 -17 1.88 -22 -28 -33 -92 -42 -56 -21
Net Income / (Loss) Continuing Operations
1.14 4.65 -17 2.07 -22 -28 -33 -92 -42 -56 -21
Total Pre-Tax Income
1.14 4.65 -17 2.07 -22 -28 -33 -92 -42 -56 -21
Total Operating Income
-0.07 -0.15 -20 -0.22 -23 -30 -49 -93 -46 -60 -37
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 -0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 -0.00 0.00 0.00 0.00
Operating Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 -0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
0.07 0.15 20 0.18 23 30 41 93 46 60 28
Selling, General & Admin Expense
0.07 0.15 1.78 - 2.50 2.66 14 6.95 6.38 11 7.90
Research & Development Expense
- - 18 - 21 27 27 - 40 49 20
Total Other Income / (Expense), net
1.17 4.81 2.34 2.37 1.08 1.66 7.84 1.30 4.07 3.73 6.54
Interest & Investment Income
1.21 2.44 2.47 2.25 1.81 1.67 3.44 3.83 3.94 3.55 3.26
Other Income / (Expense), net
- 2.36 -0.13 - -0.73 -0.01 4.39 - 0.13 0.18 3.28
Basic Earnings per Share
$0.16 $0.18 ($1,562.18) - ($54.23) ($566.46) ($1.03) ($3.31) ($526.11) ($705.20) ($0.43)
Weighted Average Basic Shares Outstanding
14.19M 23.51M 11.09K 21.16M 406.72K 50.20M 43.49M 31.14M 80.03K 80.05M 80.18M
Diluted Earnings per Share
$0.16 $0.18 ($1,562.18) - ($54.23) ($566.46) ($1.03) ($3.31) ($526.11) ($705.20) ($0.43)
Weighted Average Diluted Shares Outstanding
14.47M 23.51M 11.09K 21.24M 406.72K 50.20M 43.49M 31.14M 80.03K 80.05M 80.18M
Weighted Average Basic & Diluted Shares Outstanding
23M 23.51M 23.51M 23.51M 23.51M 23.51M 79.99M 80.03M 80.11M 80.17M 80.25M

Annual Cash Flow Statements for BridgeBio Oncology Therapeutics

This table details how cash moves in and out of BridgeBio Oncology Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
0.00 31 343
Net Cash From Operating Activities
0.00 -55 -114
Net Cash From Continuing Operating Activities
0.00 -55 -114
Net Income / (Loss) Continuing Operations
-0.04 -74 -134
Consolidated Net Income / (Loss)
-0.04 -74 -134
Depreciation Expense
- 0.21 0.28
Amortization Expense
- -1.54 -0.93
Non-Cash Adjustments To Reconcile Net Income
0.03 4.43 14
Changes in Operating Assets and Liabilities, net
0.02 16 7.16
Net Cash From Investing Activities
0.00 -121 73
Net Cash From Continuing Investing Activities
0.00 -121 73
Purchase of Property, Plant & Equipment
- -0.05 -0.61
Purchase of Investments
- -152 -84
Sale and/or Maturity of Investments
- 32 158
Net Cash From Financing Activities
0.00 206 383
Net Cash From Continuing Financing Activities
0.00 206 383
Repurchase of Common Equity
- 0.00 -12
Issuance of Preferred Equity
- 205 22
Issuance of Common Equity
0.00 0.00 373
Other Financing Activities, net
0.00 1.11 0.05

Quarterly Cash Flow Statements for BridgeBio Oncology Therapeutics

This table details how cash moves in and out of BridgeBio Oncology Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
1.84 -0.03 18 -0.09 -4.64 -0.30 379 -35 -321 1.41 22
Net Cash From Operating Activities
-0.62 -0.03 -39 -0.09 -20 -0.30 -71 -42 -36 -44 -28
Net Cash From Continuing Operating Activities
-0.62 -0.03 -39 -0.09 -20 -0.30 -71 -42 -36 -44 -28
Net Income / (Loss) Continuing Operations
1.10 2.21 -58 1.95 -22 0.92 -96 -39 -42 -56 -34
Consolidated Net Income / (Loss)
1.10 2.21 -58 1.95 -22 0.92 -96 -39 -42 -56 -34
Depreciation Expense
- - - - 0.05 - - 0.08 0.07 0.08 0.08
Amortization Expense
- - - - -0.41 - - -1.15 0.04 0.52 0.24
Non-Cash Adjustments To Reconcile Net Income
-1.25 -2.36 6.86 -2.17 0.63 -2.04 14 3.39 3.87 7.23 4.76
Changes in Operating Assets and Liabilities, net
-0.47 0.12 12 0.13 2.18 0.82 10 -5.76 2.21 4.26 0.75
Net Cash From Investing Activities
-184 - 38 - 15 - 66 7.77 -285 46 50
Net Cash From Continuing Investing Activities
-184 - 38 - 15 - 66 7.77 -285 46 50
Purchase of Property, Plant & Equipment
- - - - -0.16 - - -0.07 -0.02 -0.05 -0.01
Purchase of Investments
- - - - -24 - - -21 -312 -7.54 -17
Sale and/or Maturity of Investments
- - - - 40 - - 29 26 53 67
Net Cash From Financing Activities
186 - 20 - -0.40 - 384 -0.59 0.30 0.04 0.44
Net Cash From Continuing Financing Activities
186 - 20 - -0.40 - 384 -0.59 0.30 0.04 0.44
Repurchase of Common Equity
- - - - -0.40 - - - -0.12 - -0.04
Other Financing Activities, net
- - - - 0.00 - - 12 0.42 0.04 0.48

Annual Balance Sheets for BridgeBio Oncology Therapeutics

This table presents BridgeBio Oncology Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets
0.33 164 448
Total Current Assets
0.00 159 432
Cash & Equivalents
0.00 31 374
Short-Term Investments
- 125 52
Accounts Receivable
- 0.08 0.39
Prepaid Expenses
0.00 2.98 6.55
Plant, Property, & Equipment, net
0.00 0.49 0.96
Total Noncurrent Assets
0.33 5.12 15
Long-Term Investments
- - 0.00
Other Noncurrent Operating Assets
0.33 5.12 15
Total Liabilities & Shareholders' Equity
0.33 164 448
Total Liabilities
0.40 20 37
Total Current Liabilities
0.40 20 35
Short-Term Debt
0.07 0.48 0.00
Accounts Payable
- 3.07 1.37
Accrued Expenses
0.33 9.10 27
Current Employee Benefit Liabilities
- 3.82 5.75
Other Current Liabilities
0.00 3.11 1.06
Total Noncurrent Liabilities
0.00 0.00 2.24
Other Noncurrent Operating Liabilities
0.00 0.00 2.24
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-0.06 145 411
Total Preferred & Common Equity
-0.06 -179 411
Preferred Stock
0.00 323 0.00
Total Common Equity
-0.06 -179 411
Common Stock
0.03 44 768
Retained Earnings
-0.09 -223 -357
Accumulated Other Comprehensive Income / (Loss)
- 0.35 0.02

Quarterly Balance Sheets for BridgeBio Oncology Therapeutics

This table presents BridgeBio Oncology Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
188 190 192 196 197 485 418 377 346
Total Current Assets
2.11 2.08 2.04 1.24 0.88 476 267 242 208
Cash & Equivalents
1.84 1.81 1.79 0.96 0.66 409 53 54 76
Short-Term Investments
- - - - - 60 200 172 117
Accounts Receivable
- - - - - - 0.15 0.66 0.16
Prepaid Expenses
0.27 0.01 0.25 0.21 0.21 7.50 14 16 14
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.83 0.94 0.88 0.82
Total Noncurrent Assets
185 188 190 194 197 7.96 150 133 137
Long-Term Investments
- - - - - - 137 118 121
Other Noncurrent Operating Assets
185 188 190 194 197 7.96 14 15 16
Total Liabilities & Shareholders' Equity
188 190 192 196 197 485 418 377 346
Total Liabilities
5.54 5.60 5.65 7.39 8.15 38 45 54 53
Total Current Liabilities
0.02 0.08 0.13 1.87 2.63 36 43 52 51
Short-Term Debt
0.00 0.00 0.00 0.09 0.11 0.69 0.72 0.00 0.00
Accounts Payable
- - - - 2.52 3.65 12 6.73 10
Accrued Expenses
0.02 0.08 0.13 1.78 - 26 28 39 35
Current Employee Benefit Liabilities
- - - - - 4.49 2.02 4.39 5.27
Other Current Liabilities
- - - - - 0.51 0.54 1.54 0.80
Total Noncurrent Liabilities
5.52 5.52 5.52 5.52 5.52 2.38 2.11 1.96 1.81
Other Noncurrent Operating Liabilities
- 5.52 5.52 5.52 5.52 2.38 2.11 1.96 1.81
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-3.22 -3.37 -3.52 -6.15 -7.27 447 372 323 293
Total Preferred & Common Equity
-3.22 -3.37 -3.52 -6.15 -7.27 447 372 323 293
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-3.22 -3.37 -3.52 -6.15 -7.27 447 372 323 293
Common Stock
0.00 0.00 0.00 0.00 0.00 764 772 779 784
Retained Earnings
-3.22 -3.37 -3.52 -6.15 -7.27 -318 -399 -455 -489
Accumulated Other Comprehensive Income / (Loss)
- - - - - 0.04 -0.98 -0.96 -1.70

Annual Metrics And Ratios for BridgeBio Oncology Therapeutics

This table displays calculated financial ratios and metrics derived from BridgeBio Oncology Therapeutics' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 - 79,988,687.00
DEI Adjusted Shares Outstanding
0.00 - 79,988,687.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 - -1.68
Growth Metrics
- - -
Profitability Metrics
- - -
Net Operating Profit after Tax (NOPAT)
-0.03 -0.58 -102
Return On Investment Capital (ROIC_SIMPLE)
-447.20% 15.66% -24.80%
Earnings before Interest and Taxes (EBIT)
-0.04 -0.58 -145
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-0.04 -0.58 -146
Valuation Ratios
- - -
Leverage & Solvency
- - -
Liquidity Ratios
- - -
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
0.00 -188 -99
Efficiency Ratios
- - -
Capital & Investment Metrics
- - -
Invested Capital
0.01 187 -14
Increase / (Decrease) in Invested Capital
0.00 187 -3.40
Book Value per Share
$0.00 ($0.18) $5.14
Tangible Book Value per Share
$0.00 ($0.18) $5.14
Total Capital
0.01 189 412
Total Debt
0.07 0.00 0.53
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
0.07 -1.70 -425
Capital Expenditures (CapEx)
0.00 0.00 0.61
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.33 0.06 -28
Debt-free Net Working Capital (DFNWC)
-0.33 1.76 398
Net Working Capital (NWC)
-0.40 1.76 397
Net Nonoperating Expense (NNE)
0.01 -8.18 32
Net Nonoperating Obligations (NNO)
0.07 -1.72 -425
Total Depreciation and Amortization (D&A)
0.00 0.00 -0.65
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.00 $0.72 ($4.30)
Adjusted Weighted Average Basic Shares Outstanding
0.00 21.16M 31.14M
Adjusted Diluted Earnings per Share
$0.00 $0.72 ($4.30)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 21.24M 31.14M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 23.51M 80.03M
Normalized Net Operating Profit after Tax (NOPAT)
-0.03 -0.41 -102
Debt Service Ratios
- - -
Payout Ratios
- - -

Quarterly Metrics And Ratios for BridgeBio Oncology Therapeutics

This table displays calculated financial ratios and metrics derived from BridgeBio Oncology Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
0.00 0.00 0.00 - 0.00 0.00 0.00 79,988,687.00 80,032,823.00 80,107,104.00 80,174,267.00
DEI Adjusted Shares Outstanding
0.00 0.00 0.00 - 0.00 0.00 0.00 79,988,687.00 80,032,823.00 80,107,104.00 80,174,267.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.00 0.00 - 0.00 0.00 0.00 -1.15 -0.53 -0.70 -0.27
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Growth
0.00% 0.00% 0.00% -424.06% -3,529.91% -58.50% -143.49% - -89.69% -96.01% 24.64%
EBIT Growth
0.00% 0.00% 0.00% -424.06% -3,529.91% -58.50% -143.49% - -92.97% -99.35% 23.61%
NOPAT Growth
0.00% 0.00% 0.00% -648.66% -2,440.94% -636.40% -150.11% - -99.59% -100.00% 23.78%
Net Income Growth
0.00% 0.00% 0.00% 4,599.13% -137.89% -35.69% -158.37% - -90.91% -98.54% 34.89%
EPS Growth
0.00% 0.00% 0.00% 0.00% -125.00% -55.56% 99.93% - -870.15% -24.49% 58.25%
Operating Cash Flow Growth
0.00% 0.00% 0.00% 0.00% -18.87% -927.20% -79.51% - -83.26% -90.45% 1.40%
Free Cash Flow Firm Growth
0.00% 0.00% 0.00% 0.00% 95.03% 95.75% 186.25% - 828.66% 705.21% -114.71%
Invested Capital Growth
0.00% 0.00% 0.00% 2,865,265.86% 4.04% 3.64% -111.31% - -108.48% -111.14% -5.02%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% -52.60% -100.00% - 100.00% 0.00% 0.00%
EBITDA Q/Q Growth
-59.99% 3,417.10% -994.72% -48.78% -1,008.13% 137.93% -5,348.88% - 51.21% -29.32% 42.94%
EBIT Q/Q Growth
-59.99% 3,417.10% -994.72% -48.78% -1,008.13% 137.93% -5,348.88% - 50.53% -30.30% 42.98%
NOPAT Q/Q Growth
-128.55% -128.40% -8,935.40% -48.78% -675.69% 33.81% -2,968.75% - 50.40% -30.33% 37.71%
Net Income Q/Q Growth
2,833.89% 308.38% -472.15% -19.61% -123.03% 793.03% -1,595.23% - 54.16% -34.08% 61.92%
EPS Q/Q Growth
0.00% 12.50% -867,977.78% 0.00% 0.00% 300.00% -1,387.50% - -15,794.56% -34.04% 99.94%
Operating Cash Flow Q/Q Growth
0.00% 95.29% -135,110.50% -204.40% -736.16% 59.31% -23,528.47% - 14.96% -23.51% 36.06%
Free Cash Flow Firm Q/Q Growth
0.00% -1.11% -8.98% -1.21% 95.21% 13.60% 2,311.57% - 376.83% -2.00% -115.03%
Invested Capital Q/Q Growth
2,760,271.02% 1.07% 1.51% 1.18% 0.22% 0.68% -111.07% - -14.94% -32.22% -4.40%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% -99,026.01% 79,232.96% 0.00% - 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% -99,026.01% -96,794.48% 0.00% - 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% -99,026.01% 79,232.96% 0.00% - 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% -17,665.36% 258,266.52% 0.00% - 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 90.62% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Interest Burden Percent
-1,708.84% 210.38% 87.51% -947.38% 17.84% 325.96% 92.85% - 91.44% 94.08% 62.83%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% -0.92% -1.88% 0.00% - 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% -93.80% -298.78% 0.00% - 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.69% 2.22% 0.00% - 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.60% 3.12% -6.20% 8.06% -0.23% 0.34% 0.00% - -54.98% -71.09% -46.10%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% -200.61% -5.55% -5.68% 0.00% - 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% -1.26% 1.47% 0.00% - 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% -0.23% 4.81% 0.00% - 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-0.01% -0.06% 0.12% -0.16% 0.01% -0.01% 0.00% - -35.91% -43.82% -46.10%
Return on Equity Simple (ROE_SIMPLE)
-34.09% 0.00% 0.00% 0.00% -97.99% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-0.07 -0.15 -14 -0.22 -1.69 -1.12 -34 -65 -32 -42 -26
NOPAT Margin
0.00% 0.00% 0.00% 0.00% -69,318.21% -96,794.48% 0.00% - 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
130.89% 434.18% -379.90% 253.42% 92.88% 296.90% -4.40% - -5.03% -8.31% 1.21%
Return On Investment Capital (ROIC_SIMPLE)
2.07% 4.52% 391.35% 5.85% 27.95% 15.66% -7.70% -15.83% -8.67% -13.04% -8.94%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 99,026.01% 96,794.48% 0.00% - 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 99,026.01% 96,794.48% 0.00% - 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-0.07 2.21 -20 -0.22 -2.42 0.92 -48 -93 -46 -60 -34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-0.07 2.21 -20 -0.22 -2.42 0.92 -48 -94 -46 -59 -34
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 1.13 - 0.00 1.89 1.12
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 1.13 - 0.00 1.89 1.12
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 108,651.00 69,274.58 139,741.06 - 0.00 0.00 0.00
Price to Earnings (P/E)
137.09 41.76 0.00 28.33 42.17 53.83 0.00 - 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield
0.73% 2.39% 0.00% 3.53% 2.37% 1.86% 0.00% - 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.85 2.34 1.02 2.21 2.45 2.36 0.00 - 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 187,817.71 123,646.36 9,997.99 - 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.20 - 0.00 3.77 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Financial Leverage
-0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.74 - -0.69 -0.67 -1.06
Leverage Ratio
1.03 1.03 1.03 1.03 1.03 1.04 1.07 - 1.09 1.12 1.12
Compound Leverage Factor
-17.61 2.17 0.90 -9.78 0.18 3.38 0.99 - 1.00 1.05 0.71
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.05% 0.06% 0.15% - 0.19% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.05% 0.06% 0.15% - 0.19% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
101.77% 101.83% 101.88% 101.98% 103.22% 103.78% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital
-1.77% -1.83% -1.88% -1.98% -3.27% -3.84% 99.85% - 99.81% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 -0.03 -0.03 -0.02 - 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.30 0.14 13.99 - 2.31 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 -0.03 -0.03 -0.03 - -0.01 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.30 0.14 19.98 - 3.28 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Altman Z-Score
16.28 25.77 -0.34 23.42 21.48 18.34 7.78 - -1.05 5.22 1.97
Noncontrolling Interest Sharing Ratio
101.77% 101.83% 101.88% 102.01% 102.53% 102.85% 0.00% - 34.69% 38.36% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
90.42 26.23 16.12 10.40 0.66 0.33 13.33 - 6.16 4.69 4.08
Quick Ratio
79.01 22.93 14.09 9.05 0.51 0.25 13.11 - 5.84 4.38 3.80
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-180 -182 -199 -187 -8.96 -7.74 171 -62 171 168 -25
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - -149,654.17% -94,385.11% -218,192.31%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
180 182 185 187 187 189 -21 -14 -16 -21 -22
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
180 182 185 187 7.27 6.62 -206 -3.40 -203 -210 -1.05
Enterprise Value (EV)
334 426 189 414 459 446 36 - -387 266 13
Market Capitalization
151 240 0.12 223 266 250 504 - 0.72 610 329
Book Value per Share
($0.23) ($0.14) ($317.19) ($0.18) ($0.26) ($0.31) $10.27 $5.14 $4.65 $4.03 $3.66
Tangible Book Value per Share
($0.23) ($0.14) ($317.19) ($0.18) ($0.26) ($0.31) $10.27 $5.14 $4.65 $4.03 $3.66
Total Capital
182 184 187 189 188 189 447 412 373 323 293
Total Debt
0.00 0.00 0.00 0.00 0.09 0.11 0.69 0.53 0.72 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-1.84 -1.81 -1.79 -1.70 -0.88 -0.56 -468 -425 -388 -344 -315
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.02 0.05 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.24 0.18 0.13 0.06 -1.51 -2.31 -27 -28 -28 -35 -37
Debt-free Net Working Capital (DFNWC)
2.09 2.00 1.92 1.76 -0.54 -1.65 441 398 224 191 157
Net Working Capital (NWC)
2.09 2.00 1.92 1.76 -0.63 -1.75 440 397 223 191 157
Net Nonoperating Expense (NNE)
-1.21 -4.81 3.56 -2.09 -1.26 -4.12 10 27 9.78 14 -4.74
Net Nonoperating Obligations (NNO)
-1.84 -2.21 -1.87 -1.72 -0.88 -0.56 -468 -425 -388 -344 -315
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.07 0.11 0.60 0.32
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% -61,648.38% -64,087.51% -757,380.69% - 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% -22,256.36% -45,657.13% 12,236,098.78% - 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% -25,822.13% -48,613.76% 12,216,925.64% - 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.09 $0.20 $0.00 ($0.04) $0.08 ($1.03) ($3.31) ($526.11) ($705.20) ($0.43)
Adjusted Weighted Average Basic Shares Outstanding
14.19M 23.51M 23.51M 21.16M 23.51M 23.51M 43.49M 31.14M 80.03K 80.05M 80.18M
Adjusted Diluted Earnings per Share
$0.00 $0.09 $0.20 $0.00 ($0.04) $0.08 ($1.03) ($3.31) ($526.11) ($705.20) ($0.43)
Adjusted Weighted Average Diluted Shares Outstanding
14.47M 23.51M 23.51M 21.24M 23.51M 23.51M 43.49M 31.14M 80.03K 80.05M 80.18M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
23M 23.51M 23.51M 23.51M 23.51M 23.51M 79.99M 80.03M 80.11M 80.17M 80.25M
Normalized Net Operating Profit after Tax (NOPAT)
-0.05 -0.11 -14 -0.15 -1.69 -0.79 -34 -65 -32 -42 -26
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% -69,318.21% -67,756.13% 0.00% - 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% -17,665.36% 258,266.52% 0.00% - 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - -7.81% -4.82% -0.46%

Financials Breakdown Chart

Key Financial Trends

BBOT’s Q2 2026 statements show a well-capitalized but pre-revenue company with rapidly increasing research spending and persistent cash burn. The filings identify the reporting entity as Helix Acquisition Corp. II, so investors should verify the company and ticker alignment before relying on these figures.

Revenue remained at $0 in both Q1 and Q2 2026, continuing the company’s pre-commercial profile. The net loss widened to $56.5 million in Q2 from $42.1 million in Q1, while total operating expenses increased to $60.2 million from $46.2 million. Research and development spending rose to $49.2 million from $39.8 million, indicating a heavier investment in development activities but also greater near-term losses.

Operating cash flow was negative in every recent reported quarter. Q2 operating cash outflow increased to $44.4 million from $35.9 million in Q1 and $42.2 million in Q4 2025. The company ended Q2 with $54.1 million in cash and $171.6 million in short-term investments, while long-term investments totaled $118.4 million. Together, these liquid and investment holdings represented approximately $344.7 million, although much of the quarter’s positive investing cash flow came from selling or maturing investments rather than operating activity.

The balance sheet remains relatively strong from a leverage perspective. Total liabilities were $53.6 million, including no short-term debt, compared with $323.1 million of total common equity. However, retained earnings were negative $455.1 million, reflecting substantial cumulative losses. The company’s ability to fund operations will therefore depend on its investment portfolio, cash management and potential future financing or strategic transactions.

  • Substantial liquidity: Cash, short-term investments and long-term investments totaled approximately $344.7 million at June 30, 2026.
  • Low financial leverage: The company reported no short-term debt and total liabilities of $53.6 million against $376.7 million of total assets.
  • Strong current position: Current assets of $242.4 million were approximately 4.7 times current liabilities of $51.6 million.
  • Investment income provides some support: Interest and investment income contributed $3.6 million in Q2, partially offsetting operating expenses.
  • Investment portfolio remains central to funding: Q2 investing cash flow was positive $45.7 million, primarily because $53.3 million of investments were sold or matured after significant investment purchases in Q1.
  • Financing activity was limited: Financing provided only $37,000 in Q2 and $295,000 in Q1, suggesting that recent operations were funded primarily from existing assets rather than new capital.
  • No operating revenue: Revenue has remained effectively zero across the reported periods, leaving the company without a commercial cash-generating business.
  • Losses are worsening sequentially: Q2 net loss increased 34% from Q1, while operating expenses rose approximately 30%.
  • Persistent operating cash burn: Operating cash outflows totaled $80.3 million in the first half of 2026, compared with $64.8 million in the first half of 2025.
  • Rising dilution and cumulative deficits: Weighted-average shares increased substantially from earlier periods, while retained earnings declined to negative $455.1 million, creating ongoing dilution and profitability risks for common shareholders.
11/18/26 07:32 AM ETAI Generated. May Contain Errors.

BridgeBio Oncology Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BridgeBio Oncology Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

BridgeBio Oncology Therapeutics' net income appears to be on a downward trend, with a most recent value of -$134.04 million in 2025, falling from -$41.69 thousand in 2023. The previous period was -$74.28 million in 2024. See where experts think BridgeBio Oncology Therapeutics is headed by visiting BridgeBio Oncology Therapeutics' forecast page.

BridgeBio Oncology Therapeutics' total operating income in 2025 was -$145.82 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $145.82 million

Over the last 2 years, BridgeBio Oncology Therapeutics' total revenue changed from $0.00 in 2023 to $0.00 in 2025, a change of 0.0%.

In the past 10 quarters, BridgeBio Oncology Therapeutics' cash and equivalents has ranged from $664.23 thousand in Q2 2025 to $408.74 million in Q3 2025, and is currently $76.48 million as of their latest financial filing in Q3 2026.

BridgeBio Oncology Therapeutics had total debt of $534 thousand at the end of 2025, compared with none in 2024, and a 661.8% increase since 2023.

Over the last 2 years, BridgeBio Oncology Therapeutics' book value per share changed from 0.00 in 2023 to 5.14 in 2025.



Financial statements for NASDAQ:BBOT last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners